ABSTRACT

Introduction

Pioneering technologies such as proteomics have helped fuel the biotechnology and pharmaceutical industry with the discovery of novel targets and an intricate understanding of the activity of therapeutics and their various activities in vitro and in vivo. The field of proteomics is undergoing an inflection point, where new sensitive technologies are allowing intricate biological pathways to be better understood, and novel biochemical tools are pivoting us into a new era of chemical proteomics and biomarker discovery. In this review, we describe these areas of innovation, and discuss where the fields are headed in terms of fueling biotechnological and pharmacological research and discuss current gaps in the proteomic technology landscape.

Areas Covered

Single cell sequencing and single molecule sequencing. Chemoproteomics. Biological matrices and clinical samples including biomarkers. Computational tools including instrument control software, data analysis.

Expert Opinion

Proteomics will likely remain a key technology in the coming decade, but will have to evolve with respect to type and granularity of data, cost and throughput of data generation as well as integration with other technologies to fulfill its promise in drug discovery.

中文翻译：

---

制药和生物技术行业的蛋白质组学：展望下一个十年

摘要

介绍

蛋白质组学等开创性技术通过发现新靶点和对治疗活性及其在体外和体内的各种活动的复杂理解，帮助推动了生物技术和制药行业。蛋白质组学领域正在经历一个转折点，新的敏感技术可以让人们更好地理解复杂的生物途径，而新的生化工具正在将我们带入化学蛋白质组学和生物标志物发现的新时代。在这篇综述中，我们描述了这些创新领域，并讨论了这些领域在促进生物技术和药理学研究方面的发展方向，并讨论了蛋白质组技术领域的当前差距。

涵盖的领域

单细胞测序和单分子测序。化学蛋白质组学。生物基质和临床样本，包括生物标志物。计算工具包括仪器控制软件、数据分析。

专家意见

蛋白质组学在未来十年可能仍然是一项关键技术，但必须在数据类型和粒度、数据生成的成本和吞吐量以及与其他技术的集成方面不断发展，以实现其在药物发现方面的承诺。